LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the topline results from the LIGHTSITE IIIB Extension Trial, a prospective, open-label trial in dry (non-neovascular) age-related macular degeneration (AMD) subjects. The extension trial followed subjects that completed the pivotal LIGHTSITE III trial and resumed treatment for 13 months with the Valeda® Light Delivery System. Dry AMD is a leading cause of central v...

Today, Budweiser (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) unveils its new global platform “Celebration in the Making” and full campaign details as the Official Global Beer Sponsor of the FIFA Club World Cup 2025™. This summer, as football supporters around the globe bring their energy to the groundbreaking tournament, Budweiser will be there to elevate celebrations at every stage – from the opening touch to the final whistle, and beyond. This press release features multimedia. View the ful...

Syncron, a global leader in intelligent Service Lifecycle Management (SLM) solutions, today announced the launch of the Syncron Partner Network, an enhanced partner program designed to strengthen its global ecosystem. This initiative will enable partners to extend Syncron’s capabilities across services, sales, marketing, and product innovation—ultimately accelerating the transformation of aftermarket operations for customers worldwide. The Syncron Partner Network introduces a structured, value...

ROYC, the leading provider of complete private markets operating systems, announces the structuring of a new access fund for Private Wealth launched in collaboration with The Riverside Company. The Riverside Company is a global private equity firm focused on investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has made more than 1,000 investments and today has over $12 billion in assets under management. The firm's international private equity and ...

RHEACELL, a German biotech company specialized in the development of stem cell therapies, and AOP Health, a Europe-based leader in integrated therapies for rare diseases and in intensive care, are forming a strategic alliance. This partnership marks a crucial step toward making breakthrough therapies available to patients with high unmet medical needs – particularly those affected by Epidermolysis bullosa (EB or “butterfly children’s disease”) and chronic venous wounds. Both conditions currentl...

Cognite, the global leader in industrial AI, today announced the appointment of Torgrim Aas, Jan Eivind Danielsen, and Thorkild Stray as the inaugural class of Cognite Fellows. This landmark initiative underscores Cognite's deepening commitment to empowering customers with cutting-edge industrial Data and AI solutions while simultaneously building enduring know-how and competencies. These exceptional individuals represent the vanguard of Industrial Data and AI innovation, driving the energy tr...

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the opening of its Digital Innovation Hub at the Research and Innovation Hub of CYENS Center of Excellence. The LTIMindtree Digital Innovation Hub will enable ideation, co-creation and implementation of Advanced Digital Solutions for Eurobank, Fairfax and other EU customers and aligns with the strategic vision of the Cyprus Government to strengthen Cyprus’ role as a regional tech an...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic NPC....

Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, has published a report analyzing recent trends in obesity-related clinical trials. The report shows that the number of these trials tripled between 2019 and 2024, reflecting increased research activity and broader range of potential therapeutic options for obesity treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508533322/en/...